A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

British Journal of Haematology

Volumn 161, Issue 3, 2013, Pages 357-366

  Voorhees, Peter M ^a   Manges, Robert F ^b   Sonneveld, Pieter ^c   Jagannath, Sundar ^d   Somlo, George ^e   Krishnan, Amrita ^e   Lentzsch, Suzanne ^f   Frank, Richard C ^g   Zweegman, Sonja ^h   Wijermans, Pierre W ⁱ   Orlowski, Robert Z ^j   Kranenburg, Britte ^k   Hall, Brett ^l   Casneuf, Tineke ^l   Qin, Xiang ^l   Van de Velde, Helgi ^l   Xie, Hong ^l   Thomas, Sheeba K ^j  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b Investigative Clinical Research of Indiana   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g NORWALK HOSPITAL   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ HAGA HOSPITAL   (Netherlands)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k Janssen Biologics   (Netherlands)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

Dexamethasone; Interleukin 6; Multiple myeloma; Siltuximab; Targeted therapy

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; C REACTIVE PROTEIN; CORTICOSTEROID; DEXAMETHASONE; HEPCIDIN; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; SILTUXIMAB; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CELLULITIS; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPERTRIGLYCERIDEMIA; INBORN ERROR OF METABOLISM; INFECTION; INFUSION RELATED REACTION; INSOMNIA; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THRUSH; TIME TO PROGRESSION; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VIRUS REACTIVATION; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; C-REACTIVE PROTEIN; DEXAMETHASONE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFECTION CONTROL; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SALVAGE THERAPY;

EID: 84876196796     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12266     Document Type: Article

References (35)

1. Anderson, K.C., Jones, R.M., Morimoto, C., Leavitt, P. & Barut, B.A. (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood, 73, 1915-1924.
2. Anderson, K.C., Kyle, R.A., Rajkumar, S.V., Stewart, A.K., Weber, D., Richardson, P., on behalf of the ASHTM/FDA Panel on Clinical Endpoints in Multiple Myeloma (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia, 22, 231-239.
3. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
4. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S. & Anderson, K.C. (1997) Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 15, 837-843.
5. Cheung, W.C. & Van Ness, B. (2001) The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia, 15, 264-271.
6. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. & International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
7. Ferlin-Bezombes, M., Jourdan, M., Liautard, J., Brochier, J., Rossi, J.F. & Klein, B. (1998) IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. Journal of Immunology, 161, 2692-2699.
8. Fulciniti, M., Hideshima, T., Vermot-Desroches, C., Pozzi, S., Nanjappa, P., Shen, Z., Patel, N., Smith, E.S., Wang, W., Prabhala, R., Tai, Y.T., Tassone, P., Anderson, K.C. & Munshi, N.C. (2009) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical Cancer Research, 15, 7144-7152.
9. Grigorieva, I., Thomas, X. & Epstein, J. (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Experimental Hematology, 26, 597-603.
10. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H. & Epstein, J. (1994) Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, 84, 3063-3070.
11. Honemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dorken, B. & Bargou, R.C. (2001) The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. International Journal of Cancer, 93, 674-680.
12. Hunsucker, S.A., Magarotto, V., Kuhn, D.J., Kornblau, S.M., Wang, M., Weber, D.M., Thomas, S.K., Shah, J.J., Voorhees, P.M., Xie, H., Cornfeld, M., Nemeth, J.A. & Orlowski, R.Z. (2011) Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. British Journal of Haematology, 152, 579-592.
13. Juge-Morineau, N., Francois, S., Puthier, D., Godard, A., Bataille, R. & Amiot, M. (1995) The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. British Journal of Haematology, 90, 707-710.
14. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83-85.
15. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
16. Kumar, S.K., Therneau, T.M., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Witzig, T.E., Lust, J.A., Larson, D.R., Kyle, R.A. & Greipp, P.R. (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clinic Proceedings, 79, 867-874.
17. Kurzrock, R., Voorhees, P.M., Casper, C., Furman, R.R., Fayad, L., Lonial, S., Borghaei, H., Jagannath, S., Sokol, L., Usmani, S., van de Velde, H., Qin, X., Qi, M., Cornfeld, M.J. & van Rhee, F. (2011) Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. Blood (ASH Annual Meeting Abstracts), 118, Abstract 3959.
18. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R. & Berenson, J. (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunology, 162, 248-255.
19. Liu, P., Oken, M. & Van Ness, B. (1999) Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia, 13, 473-480.
20. Maini, R.N., Taylor, P.C., Szechinski, J., Pavelka, K., Broll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., Thomson, D. & Kishimoto, T. & CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis & Rheumatism, 54, 2817-2829.
21. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J.F., Klein, B. & Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood, 103, 3148-3157.
22. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K. & Ganz, T. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113, 1271-1276.
23. Niesvizky, R., Richardson, P.G., Rajkumar, S.V., Coleman, M., Rosinol, L., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Boral, A.L., Esseltine, D.L., Anderson, K.C. & Blade, J. (2008) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 143, 46-53.
24. Orlowski, R.Z., Gercheva, L., Williams, C., Sutherland, H.J., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M.A., Cavenagh, J.D., Spicka, I., Maiolino, A., Suvorov, A., Blade, J., Samoilova, O.S., Van De Velde, H., Bandekar, R., Kranenburg, B., Xie, H. & Rossi, J.-F. (2012) Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma. Journal of Clinical Oncology (ASCO Meeting Abstracts), 30, 8018.
25. Puchalski, T., Prabhakar, U., Jiao, Q., Berns, B. & Davis, H.M. (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clinical Cancer Research, 16, 1652-1661.
26. Rajkumar, S.V., Harousseau, J.L., Durie, B., Anderson, K.C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., Jagannath, S., Facon, T., Avet-Loiseau, H., Lonial, S., Palumbo, A., Zonder, J., Ludwig, H., Vesole, D., Sezer, O., Munshi, N.C. & San Miguel, J. & International Myeloma Workshop Consensus Panel 1 (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 117, 4691-4695.
27. van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., Qin, X., Herring, J., Casper, C. & Kurzrock, R. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. Journal of Clinical Oncology, 28, 3701-3708.
28. Rossi, J.F., Negrier, S., James, N.D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P. & Berns, B. (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. British Journal of Cancer, 103, 1154-1162.
29. Rowley, M., Liu, P. & Van Ness, B. (2000) Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood, 96, 3175-3180.
30. Tassone, P., Neri, P., Burger, R., Savino, R., Shammas, M., Catley, L., Podar, K., Chauhan, D., Masciari, S., Gozzini, A., Tagliaferri, P., Venuta, S., Munshi, N.C. & Anderson, K.C. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clinical Cancer Research, 11, 4251-4258.
31. Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. & Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 3712-3720.
32. Voorhees, P.M., Chen, Q., Kuhn, D.J., Small, G.W., Hunsucker, S.A., Strader, J.S., Corringham, R.E., Zaki, M.H., Nemeth, J.A. & Orlowski, R.Z. (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clinical Cancer Research, 13, 6469-6478.
33. Voorhees, P.M., Chen, Q., Small, G.W., Kuhn, D.J., Hunsucker, S.A., Nemeth, J.A. & Orlowski, R.Z. (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. British Journal of Haematology, 145, 481-490.
34. Xu, F., Gardner, A., Tu, Y., Michl, P., Prager, D. & Lichtenstein, A. (1997) Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. British Journal of Haematology, 97, 429-440.
35. van Zaanen, H.C., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O., van der Lelie, J. & van Oers, M.H. (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal of Haematology, 102, 783-790.